SOURCE: Proteonomix


December 29, 2009 11:00 ET

Proteonomix, Inc. (PROT) Announces Change in Officers/Directors

MOUNTAINSIDE, NJ--(Marketwire - December 29, 2009) - Proteonomix, Inc. (PINKSHEETS: PROT) announces that Joel Pensley has resigned as secretary, director and general counsel and Roger Fidler has joined the Company as director and general counsel; and Steven Byle, presently a director, has assumed the role of secretary.

Mr. Pensley, 68 years old, resigned as an officer and director of Proteonomix due to health concerns.

Mr. Fidler has been the sole director, President, Chief Executive and Financial Officer of Global Agri-Med Technologies, Inc., a corporation that is publicly traded in the pink sheets, since inception in October 28, 1999. Mr. Fidler has been engaged in the private practice of law since 1983, specializing in corporate and securities law. Mr. Fidler has previously served on the Boards of Directors and as an officer of several other publicly held corporations, including Diehl Graphsoft, Inc., D-Lanz Development Group, Inc., the Leonard Swindbourne Acquisition Corp., and numerous private companies. Mr. Fidler received a B.S. degree in Physics from Dickinson College, Carlisle, Pennsylvania in 1972; a Masters of Science degree from the University of Illinois at Champaign-Urbana, Illinois in 1974; and a Juris Doctor from the University of South Carolina in 1977 where he was a member of the Law Review. He is a member of the bars of New Jersey, New York and the District of Columbia and has practiced before the federal and state courts in New York and New Jersey as well as pro hac vice in cases before Federal District Courts in Kentucky and Florida. In addition he is a patent attorney authorized to practice before the United States Patent and Trademark Office.

Michael Cohen, CEO, Proteonomix, stated: "We wish Mr. Pensley a speedy recovery. Although we regret that Mr. Pensley resigned from his management positions, we are pleased that Roger Fidler has joined our team. He is an experienced attorney with a patent law as well as a scientific and business background. We look forward to working with Mr. Fidler. We are also pleased Steven Byle will assume the role of secretary. He is already a director and is an experienced attorney and businessman."

Mr. Fidler stated: "I trust that my background and skills can mesh with the scientific advances of Proteonomix and its subsidiaries. I hope to assist Mr. Cohen, and his colleagues in the development and growth of the Company."

About Proteonomix, Inc.

Proteonomix, Inc. is a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives. Proteonomix has facilities at a number of academic institutions. Its subsidiary, Proteoderm, Inc. has developed a line of anti-aging cosmetics; visit,, and

Safe Harbor: Under the Private Securities Litigation Reform Act of 1995, statements herein relating to the Company's expectations are forward-looking statements. The anticipated results, including the entering into an agreement reflecting the terms of the letter of intent and performance pursuance thereto may not occur.

Contact Information

  • Contact:
    Michael Cohen
    Proteonomix, Inc.
    (973) 544-6116